PCI The Journeys Within
CPHI 2026 – 23/07/2026

Current Edition

Current Features

Advertisement

Current features

The Balancing Act of a Single Pivotal Trial in Ophthalmology

The US regulatory environment has evolved substantially since the federal government first started to regulating food production and drug development. The initial re...
Continue Reading →
Current features

Clinical Supply Distribution Strategy: Planning for Flexibility in a Changing Trial Landscape

The clinical trial ecosystem is undergoing a structural shift. What was once a relatively linear, site-centric model has evolved into a complex, globally distributed...
Continue Reading →
Current features

The Net Treatment Benefit and Project Optimus

What is FDA’s Project Optimus? The FDA’s Project Optimus is a key step toward improving dose optimisation in oncology. Originally announced in 2021, the guidance...
Continue Reading →
Current features

AI in Clinical Trials: From Pilot to Production

Clinical research associates (CRAs) do not replace investigators, radiologists or central readers and they do not independently perform a medical interpretation of i...
Continue Reading →
Current features

Trust, Not Accuracy: Why Pharmacovigilance Teams Still Double-Check AI Output They Know to be Valid

AI output being correct doesn’t automatically equate to it being trusted. Some pharma companies that have been drawing on AI powered adverse event processing for a w...
Continue Reading →
Current features

Beyond One-Time RECIST 1.1 Training: Knowledge Acquisition and Retention

Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) provides standardised criteria for evaluating changes in tumour burden in solid-tumour clinica...
Continue Reading →
Quotient
CPHI 2026 – 20/07/2026

Company Profiles